JPMorgan Chase & Co. Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price increased by analysts at JPMorgan Chase & Co. from $107.00 to $122.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 32.26% from the stock’s previous close.

KNSA has been the subject of several other reports. The Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.57.

Kiniksa Pharmaceuticals International Trading Down 5.5%

Shares of Kiniksa Pharmaceuticals International stock traded down $5.32 during trading hours on Friday, reaching $92.24. 1,320,137 shares of the company’s stock were exchanged, compared to its average volume of 702,945. The company has a 50 day moving average of $78.88 and a two-hundred day moving average of $59.78. The stock has a market cap of $7.20 billion, a P/E ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International has a fifty-two week low of $36.56 and a fifty-two week high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. As a group, analysts expect that Kiniksa Pharmaceuticals International will post 1.16 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares in the company, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Bank of America Corp DE grew its holdings in shares of Kiniksa Pharmaceuticals International by 220.9% during the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after buying an additional 506,576 shares during the last quarter. Rubric Capital Management LP raised its stake in Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares in the last quarter. Janus Henderson Group PLC raised its stake in Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after buying an additional 327,595 shares during the last quarter. Spruce Street Capital LP raised its position in Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after buying an additional 128,417 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.